Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Reijo Salonen"'
Autor:
Andrew Scott, Reijo Salonen
Publikováno v:
Current Pain and Headache Reports. 6:133-139
Headache care specialists agree that the introduction of sumatriptan constitutes a major advance in headache therapy, but they differ about whether other triptans offer clinically significant advantages over sumatriptan. This article examines this is
Autor:
Reijo Salonen
Publikováno v:
Cephalalgia. 20:25-32
Comparing therapeutic agents in a drug class can be difficult. This article examines the ways in which the triptans can be and have been compared and evaluates the advantages and disadvantages of the approaches. Direct comparative trials are clearly
Publikováno v:
Cephalalgia. 18:273-277
With an onset of headache relief as early as 15 min postdose compared with placebo, sumatriptan nasal spray is an important treatment option for patients who seek rapid headache relief and/or a convenient dosing form, whose migraine-associated nausea
Publikováno v:
Headache: The Journal of Head and Face Pain. 40:605-607
Autor:
Andrew J. Dowson, Carl Dahlöf, Hank Mansbach, Christopher J. Webster, Stewart J. Tepper, Martin Jones, Ba Pham, Reijo Salonen, Lawrence C. Newman
Publikováno v:
Headache. 44(9)
Context.—Headache experts have suggested that to improve the recognition of migraine, patients with a stable pattern of episodic, disabling headache and a normal physical exam should be considered to have migraine in the absence of contradictory ev
Autor:
Antony Sabin, Peter Coates, Mark Leibowitz, Helen Purdon, Alan Metz, Stephen O'Quinn, Adrian Pereira, Reijo Salonen, Olivier Petricoul, Eliane Fuseau, Scott McNeal, Stephen Thein
Publikováno v:
Clinical therapeutics. 23(2)
Background: Some comparative trials of selective serotonin 1B/1D-agonists in migraine have reported ∼15% lower efficacy for sumatriptan tablets than that reported in placebo-controlled trials. Objective: This study was designed to test the hypothes
Autor:
Reijo Salonen, Jane Saiers
Publikováno v:
Cephalalgia : an international journal of headache. 19(1)
Menstrual migraine may be debilitating, long-lasting, and refractory to treatment. Because the efficacy and tolerability of abortive and prophylactic treatment options for menstrual migraine have generally not been evaluated in controlled clinical tr
Publikováno v:
Scopus-Elsevier
A major barrier to optimal care in Parkinson’s disease (PD) is the many years it takes for patients to gain access to new therapies and the best neurological services. A new treatment has to overcome many hurdles to become a clinically and cost-eff
Publikováno v:
Cephalalgia. 21:933-934